Clinerion patient recruitment system selected as official service for ICN members

By Melissa Fassbender contact

- Last updated on GMT

Up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment. (Image: iStock/Weedezign)
Up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment. (Image: iStock/Weedezign)

Related tags: Patient recruitment, Clinical trial

The International Clinical Trial Center Network (ICN) adopts Clinerion's patient recruitment system as an official service to help its members speed trail startup.

Clinerion’s system brings automated medical informatics solutions for protocol design, site selection, and patient recruitment​ to members of the ICN – a network of academic and government-based research institutions worldwide.

According to Ulf Claesson, Clinerion’s CEO, what makes the patient recruitment system (PRS) unique is a combination of three elements: “real-time search (so patients can be identified as they arrive at the hospital), a hybrid network of federated local installations at hospitals, and complete protocol definition and feasibility check​,” he told Outsourcing-Pharma.com.

Hospitals can get more visibility for having trials sited, leading to more revenue from trials and a better reputation for research, without having to develop their own query systems​,” added Claesson.

Through automation Clinerion is able to identify candidate patients​ and their locations in minutes, speeding up site selection and discussions with trial sites on placing the trials. With traditional methods, 48% of sites miss their enrollment targets for Phase II or III studies, resulting in timelines nearly double the original duration to meet desired enrollment levels.

Additionally, through the PRS protocols can be checked in real-time, removing the need for many protocol amendments iterations, which can be extremely costly​, with each amendment costing an estimated $450,000 – and often more than 3.5 amendments are required for Phase III trial protocols.

Each day a drug is delayed from reaching the market, the pharmaceutical company loses up to $8 million​,” added Claesson, and up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment.

We are grateful to the ICN for adopting us, as it means that the premier research hospitals of the world have acknowledged the benefits PRS brings to the clinical trials process​,” said Claesson.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars